Prelude Capital Management’s Pacira BioSciences PCRX Stock Holding History

Prelude Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,000	Closed	-$75K	–	1618
2017 Q3	$75K	Buy	+2,000	New	+$80.5K	0.01%	973
2017 Q2	–	Sell	-2,500	Closed	-$114K	–	1787
2017 Q1	$114K	Buy	+2,500	New	+$108K	0.01%	748
2016 Q4	–	Sell	-23,200	Closed	-$794K	–	1726
2016 Q3	$794K	Buy	+23,200	New	+$909K	0.08%	243

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's PCRX Position: Q1 2026 in Review

Prelude Capital Management increased its Pacira BioSciences (PCRX) stake by 15% in Q1 2026, buying an estimated $150K and bringing the position to 50,735 shares worth $1.15M. The position accounts for 0.09% of the portfolio, ranked #274.

Prelude Capital Management first reported a position in PCRX in Q2 2014 and has held it in 26 quarters since. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Prelude Capital Management held 50,735 shares of Pacira BioSciences worth $1.15M as of Q1 2026.
Prelude Capital Management bought 6,740 Pacira BioSciences shares in Q1 2026, an estimated $150K.
Pacira BioSciences made up 0.09% of Prelude Capital Management's portfolio in Q1 2026, its #274 holding.
Prelude Capital Management first reported a position in Pacira BioSciences in Q2 2014 and has held it in 26 quarters since.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.